Language:

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

Oncotarget, 2017-07, Vol.8 (30), p.49548-49563

Copyright: © 2017 Chretien et al. 2017 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.17747 ;PMID: 28548938

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
Author: Chretien, Anne-Sophie ; Fauriat, Cyril ; Orlanducci, Florence ; Rey, Jerome ; Borg, Gaelle Bouvier ; Gautherot, Emmanuel ; Granjeaud, Samuel ; Demerle, Clemence ; Hamel, Jean-François ; Cerwenka, Adelheid ; von Strandmann, Elke Pogge ; Ifrah, Norbert ; Lacombe, Catherine ; Cornillet-Lefebvre, Pascale ; Delaunay, Jacques ; Toubert, Antoine ; Arnoulet, Christine ; Vey, Norbert ; Olive, Daniel
Subjects: Adult ; Biomarkers ; Bone Marrow - pathology ; Female ; Gene Expression ; Gene Expression Regulation, Leukemic ; Genetic Testing ; Humans ; Kaplan-Meier Estimate ; Killer Cells, Natural - immunology ; Killer Cells, Natural - metabolism ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - immunology ; Leukemia, Myeloid, Acute - mortality ; Ligands ; Male ; Middle Aged ; Natural Cytotoxicity Triggering Receptor 3 - genetics ; Prognosis ; Proportional Hazards Models ; Research Paper
Is Part Of: Oncotarget, 2017-07, Vol.8 (30), p.49548-49563
Description: Cytogenetics and European Leukemia Net (ELN) genetic classification predict patients at increased risk of relapse in acute myeloid leukemia (AML) except in the intermediate risk group for which further prognostic determinants are required. We have previously shown that Natural Killer (NK) cell defects in AML are predictors of poor overall survival (OS). This study aimins at validating NKp30, a receptor that mediates NK activation, as a prognostic biomarker for AML patients with intermediate prognosis.NKp30 expression was prospectively assessed at diagnosis on NK cells from peripheral blood by flow cytometry (N = 201 patients). Clinical outcome was evaluated with regard to NKp30 status.In patients with intermediate cytogenetic (N = 162), NKp30high phenotype at diagnosis was predictive of better OS (HR = 0.26; 95%CI = [0.14-0.50]; P < 0.0001) and relapse-free survival (RFS) (HR = 0.21; 95%CI = [0.08-0.52]; P = 0.0007). In patients with intermediate ELN (N = 116), NKp30high phenotype at diagnosis was predictive of better OS (HR = 0.33; 95%CI = [0.16-0.67]; P = 0.0019) and RFS (HR = 0.24; 95%CI = [0.08-0.67]; P = 0.0058). In multivariate analysis, high NKp30 expression independently predicted improved OS (HR = 0.56, P = 0.046) and RFS (HR = 0.37, P = 0.048). Consistently, cumulative incidence of relapse (CIR) was lower in patients with high NKp30 expression (HR = 0.37, P = 0.026).In conclusion, we propose NKp30 status as a simple and early prognostic biomarker that identifies intermediate-risk patients with poor prognosis who otherwise may not be identified with existing risk stratification systems.
Publisher: United States: Impact Journals LLC
Language: English
Identifier: ISSN: 1949-2553
EISSN: 1949-2553
DOI: 10.18632/oncotarget.17747
PMID: 28548938
Source: GFMER Free Medical Journals
MEDLINE
PubMed Central
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

Copyright: © 2017 Chretien et al. 2017 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.17747 ;PMID: 28548938

Searching Remote Databases, Please Wait